QUASAR2 Study

Publication Reference

1. Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, Weaver A, Church D, Scudder C, Pearson S, Julier P, Pezzella F, Tomlinson I, Domingo E, Kerr DJ. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncology 2016; 17(11): 1543–1557.
2. Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent DJ, Green E, McLeod H, Zanger UM, Schwag M, Seymour MT, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley RS, Kerr D, Tomlinson I. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. Journal of Clinical Oncology 2014; 32(10): 1031–1039.

Conference Presentation Reference

1. Midgley RS, Love S, Potter V, Segelov E, Ferry DR, Weaver A, Scudder C, Grumett S, Julier P, Kerr DJ. Capecitabine ± bevacizumab in the adjuvant treatment of colorectal cancer: first and final toxicity results from the international phase III Quasar 2 trial. European Society for Medical Oncology (ESMO) 37th Annual Congress; 28 Sep–2 Oct 2012; Vienna.
2. Segelov E, Ransom D, Eek R, Begbie S, Price T, Chong G, Jeffery M, Platell C, Solomon M, Farmer C, Wilson K, Roff K, Simes J, Hewett P.. QUASAR2: A multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne.
3. Frenel J, Carreira S, Goodall J, Roda-Perez D, Smith A, Mateo J, Ong M, Gasi-Tendefelt D, Yap TA, Attard G, Nava-Rodrigues D, Molife LR, Kaye SB, Banerji U, deBono JS. Serial next generation sequencing of CFDNA to monitor phase I targeted drug administration. European Society for Medical Oncology Congress; 26–30 Sep 2014; Madrid.
4. Midgley RS, Love S, Tomlinson I, Johnstone E, Scudder C, Pearson SR, Julier P, Domingo E, Church D, Pezzela F, Hu J, Segelov E, Weaver A, Kerr DJ. Final results from QUASAR2, a multicentre, international randomised phase III trial of capecitabine ± bevacizumab in the adjuvant setting of stage II/III colorectal cancer. European Society for Medical Oncology Congress; 26–30 Sep 2014; Madrid.

Aim

QUASAR2 uses a new combination for adjuvant therapy: an oral chemotherapy drug (capecitabine) and a molecularly targeted therapy (bevacizumab), to define whether this is superior in efficacy and less in toxicity than capecitabine alone.